RyR2 disease mutations at the C-terminal domain intersubunit interface alter closed-state stability and channel activation.

Ryanodine receptors (RyRs) are ion channels that mediate the release of Ca ²⁺ from the sarcoplasmic reticulum/endoplasmic reticulum, mutations of which are implicated in a number of human diseases. The adjacent C-terminal domains (CTDs) of cardiac RyR (RyR2) interact with each other to form a ring-like tetrameric structure with the intersubunit interface undergoing dynamic changes during channel gating. This mobile CTD intersubunit interface harbors many disease-associated mutations. However, the mechanisms of action of these mutations and the role of CTD in channel function are not well understood. Here, we assessed the impact of CTD disease-associated mutations P4902S, P4902L, E4950K, and G4955E on Ca ²⁺ - and caffeine-mediated activation of RyR2. The G4955E mutation dramatically increased both the Ca ²⁺ -independent basal activity and Ca ²⁺ -dependent activation of [ ³ H]ryanodine binding to RyR2. The P4902S and E4950K mutations also increased Ca ²⁺ activation but had no effect on the basal activity of RyR2. All four disease mutations increased caffeine-mediated activation of RyR2 and reduced the threshold for activation and termination of spontaneous Ca ²⁺ release. G4955D dramatically increased the basal activity of RyR2, whereas G4955K mutation markedly suppressed channel activity. Similarly, substitution of P4902 with a negatively charged residue (P4902D), but not a positively charged residue (P4902K), also dramatically increased the basal activity of RyR2. These data suggest that electrostatic interactions are involved in stabilizing the CTD intersubunit interface and that the G4955E disease mutation disrupts this interface, and thus the stability of the closed state. Our studies shed new insights into the mechanisms of action of RyR2 CTD disease mutations.
Competing Interests: Conflict of interest W. G. is a recipient of the Alberta Innovates-Health Solutions Graduate Studentship Award; J. W. is a recipient of the Libin Cardiovascular Institute and Cumming School of Medicine Postdoctoral Fellowship Award; B. S. is a recipient of the Heart and Stroke Foundation of Canada Junior Fellowship Award and the Alberta Innovates-Health Solutions Fellowship Award; and S. R. W. C. is the Heart and Stroke Foundation Chair in cardiovascular research. All other authors declare that they have no conflicts of interest with the contents of this article.
(Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)